Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Veliparib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Sep 2017 Status changed from recruiting to completed.
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
- 27 Oct 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.